Human glandular kallikrein

Immunohistochemical studies demonstrated that tissue expression of hK2 showed intense staining in high-grade cancers and lymph node metastases, whereas it showed weaker staining for low-grade cancers and BPH. Serum hK2 alone or hK2 total PSA/free PSA has been shown to be 

Currently, there are two major hK2 immunoassays. Hease and colleagues found notable differences in values measured by the two immunoassays for hK2 for identical patient samples. Calibration of the two assays by use of a common, ek-rhK2-based calibrator revealed a substantial gain in agreement between the assays. 

---

Prostate-specific antigen (PSA, hK3) and, more recently, human glandular kallikrein 2 (hK2) are used as tumor markers for prostate cancer. Several... 

KLK2 Human glandular kallikrein 1, hGK-1 M18157 Hs.181350 SOI.161 P20151... 

The association of kallikreins with cancer is well established. PSA (hK3) and, more recently, human glandular kallikrein (hK2) are useful biomarkers for prostate cancer. A more detailed discussion about hK2 and hK3 as cancer biomarkers can be found elsewhere [31]. In addition to its established role in prostate cancer diagnosis and monitoring, recent reports indicate that hK3 can be useful as a marker for breast cancer prognosis [215],... 

Riegman PH, Vlietstra RJ, Klaassen P, et al. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEB Lett 1989 247 123-126. 

Schedlich LJ, Bennetts BH, Morris BJ. Primary structure of a human glandular kallikrein gene. DNA 1987 6 429-437. 

Lundwall A. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem Biophys Res Commun 1989 161 1151-1159. 

Stenman UH. New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease [editorial comment], Clin Chem 1999 45 753-754. 

Grauer LS, Finlay JA, Mikolajczyk SD, Pusateri KD, Wolfert RL. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J Androl 1998 19 407 111. 

Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen [see comments], Clin Chem 1999 45 790-799. 

Heeb MJ, Espana F. alpha2-macroglobulin and Cl-inactivator are plasma inhibitors of human glandular kallikrein. Blood Cell Mol Dis 1998 24 412 119. 

Cao Y, Lundwall A, Gadaleanu V, Lilja H, Bjartell A. Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2. Am J Pathol 2002 161 2053-2063. 

Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997 238 549-555. 

Riegman PH, Vlietstra RJ, van der Korput HA, Romijn JC, Trapman J. Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol 1991 76 181-190. 

Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 1997 272 21582-21588. 

Slawin KM, Shariat SF, Nguyen C, et al. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. Cancer Res 2000 60 7142-7148. 

Magklara A, Scorilas A, Stephan C, et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 2000 56 527-532. 

Darson MF, PaceUi A, Roche P, et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999 53 939. 

Haese A, Graefen M, Steuber T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below lOng/ml. Prostate 2001 49 101. 

Haese A, Vaisanen V, Finlay JA, et al. Standardization of two immunoassays for human glandular kallikrein 2. Clin Chem 2003 9 601-10. 

J. Rapp, B. Dowell, T. Lovgren, K. Pettersson, H. Lilja. Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. Protein Sci. 1998, 7, 259-269. 

---